$2.79 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 103 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | NEVRO CORPnote 1.750% 6/0 | $99,400,000 | +232.3% | 100,000,000 | +262.3% | 3.56% | +239.1% | |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $94,815,000 | +190.0% | 1,540,448 | +218.2% | 3.40% | +195.8% |
| New | DEXCOM INCnote 0.750% 5/1 | $84,160,000 | – | 55,000,000 | +100.0% | 3.02% | – | |
| MYL | Buy | MYLAN N V | $67,421,000 | +7.1% | 1,842,111 | +5.7% | 2.42% | +9.2% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $65,392,000 | +19.7% | 2,455,586 | +69.7% | 2.34% | +22.0% |
| ANAB | Buy | ANAPTYSBIO INC | $64,598,000 | +61.5% | 647,466 | +15.0% | 2.31% | +64.7% |
| ECYT | Buy | ENDOCYTE INC | $62,410,000 | +94.6% | 3,514,084 | +51.2% | 2.24% | +98.6% |
| XENT | Buy | INTERSECT ENT INC | $61,754,000 | +61.7% | 2,147,950 | +110.6% | 2.21% | +65.0% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $52,729,000 | +51.8% | 6,910,789 | +14.0% | 1.89% | +54.8% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $50,145,000 | +65.4% | 1,424,571 | +92.2% | 1.80% | +68.6% |
| ARGX | Buy | ARGENX SEsponsored adr | $49,789,000 | +34.4% | 656,500 | +46.9% | 1.78% | +37.0% |
| BKD | Buy | BROOKDALE SR LIVING INC | $46,279,000 | +120.8% | 4,707,912 | +104.2% | 1.66% | +125.3% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $44,916,000 | -18.1% | 3,093,416 | +12.7% | 1.61% | -16.5% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $40,982,000 | +35.9% | 525,000 | +10.5% | 1.47% | +38.6% |
| EHTH | Buy | EHEALTH INC | $34,677,000 | +42.0% | 1,227,061 | +11.1% | 1.24% | +44.8% |
| IMMU | Buy | IMMUNOMEDICS INC | $33,120,000 | +24.4% | 1,590,000 | +41.4% | 1.19% | +26.8% |
| NVRO | New | NEVRO CORP | $29,927,000 | – | 525,040 | +100.0% | 1.07% | – |
| GLPG | Buy | GALAPAGOS NVspon adr | $29,239,000 | +92.2% | 260,064 | +57.6% | 1.05% | +96.1% |
| VCEL | New | VERICEL CORP | $22,891,000 | – | 1,617,730 | +100.0% | 0.82% | – |
| ARVN | New | ARVINAS INC | $20,813,000 | – | 1,233,734 | +100.0% | 0.75% | – |
| RGNX | Buy | REGENXBIO INC | $20,763,000 | +131.5% | 275,000 | +120.0% | 0.74% | +136.2% |
| FATE | New | FATE THERAPEUTICS INC | $19,118,000 | – | 1,173,617 | +100.0% | 0.68% | – |
| EPZM | Buy | EPIZYME INC | $18,858,000 | -15.1% | 1,779,094 | +8.5% | 0.68% | -13.3% |
| DPLO | New | DIPLOMAT PHARMACY INC | $16,570,000 | – | 853,687 | +100.0% | 0.59% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $14,372,000 | – | 650,000 | +100.0% | 0.52% | – |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $10,210,000 | – | 499,747 | +100.0% | 0.37% | – |
| ALLK | New | ALLAKOS INC | $10,123,000 | – | 225,000 | +100.0% | 0.36% | – |
| LIVN | New | LIVANOVA PLC | $8,864,000 | – | 71,500 | +100.0% | 0.32% | – |
| QURE | New | UNIQURE NV | $8,786,000 | – | 241,430 | +100.0% | 0.32% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $8,089,000 | – | 475,000 | +100.0% | 0.29% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $8,013,000 | – | 460,000 | +100.0% | 0.29% | – |
| INSP | New | INSPIRE MED SYS INC | $7,953,000 | – | 189,000 | +100.0% | 0.28% | – |
| NVTRQ | Buy | NUVECTRA CORP | $6,130,000 | +128.0% | 278,890 | +112.9% | 0.22% | +134.0% |
| ADUS | New | ADDUS HOMECARE CORP | $4,601,000 | – | 65,590 | +100.0% | 0.16% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $4,279,000 | – | 635,843 | +100.0% | 0.15% | – |
| EIDX | Buy | EIDOS THERAPEUTICS INC | $4,196,000 | -36.3% | 420,409 | +29.8% | 0.15% | -35.1% |
| SVRA | New | SAVARA INC | $2,790,000 | – | 250,000 | +100.0% | 0.10% | – |
| RMED | New | RA MED SYS INC | $2,341,000 | – | 128,600 | +100.0% | 0.08% | – |
| PTXTQ | New | PERNIX THERAPEUTICS HLDGS IN | $635,000 | – | 658,826 | +100.0% | 0.02% | – |
| HSGX | New | HISTOGENICS CORP | $161,000 | – | 296,099 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.